KINOX GAS

Pays: Canada

Langue: anglais

Source: Health Canada

Ingrédients actifs:

NITRIC OXIDE

Disponible depuis:

AIRGAS THERAPEUTICS LLC

Code ATC:

R07AX01

DCI (Dénomination commune internationale):

NITRIC OXIDE

Dosage:

800PPM

forme pharmaceutique:

GAS

Composition:

NITRIC OXIDE 800PPM

Mode d'administration:

INHALATION

Unités en paquet:

362L/2138L

Type d'ordonnance:

Prescription

Domaine thérapeutique:

NITRATES AND NITRITES

Descriptif du produit:

Active ingredient group (AIG) number: 0151361002; AHFS:

Statut de autorisation:

APPROVED

Date de l'autorisation:

2016-12-01

Résumé des caractéristiques du produit

PRODUCT MONOGRAPH
PR KINOX™
nitric oxide for inhalation
100 ppm
800 ppm
Manufactured by:
Airgas Therapeutics LLC
6141 Easton Road
Plumsteadville, Pennsylvania
18949-0310 USA
Importer:
VitalAire Canada Inc.
8 Bram Court
Brampton, Ontario
L6W 3R6
Control Number: 260152
KINOX is a trademark of Air Liquide Sante (International), Société
Anonyme.
Date of
Preparation:
January 25, 2016
Date of Revision:
February 15, 2022
Page 2 of 26
PRODUCT MONOGRAPH
PR KINOX™
NITRIC OXIDE FOR INHALATION
100 ppm
800 ppm
ACTIONS AND CLINICAL PHARMACOLOGY
Nitric oxide is a compound produced by many cells of the body. It
relaxes vascular smooth muscle
by binding to the heme moiety of cytosolic guanylate cyclase,
activating guanylate cyclase and
increasing intracellular levels of cyclic guanosine
3’,5’-monophosphate, which then leads to
vasodilation. When inhaled, nitric oxide produces selective pulmonary
vasodilation. Nitric oxide
is very rapidly inactivated by binding to hemoglobin. Thus, delivered
via inhalation, nitric oxide
improves V/Q matching and is a selective pulmonary vasodilation agent.
Inhaled nitric oxide appears to increase the partial pressure of
arterial oxygen (PaO
2
) by dilating
pulmonary vessels in better ventilated areas of the lung,
redistributing pulmonary blood flow away
from lung regions with low ventilation/perfusion (V/Q) ratios toward
regions with normal ratios.
Effects on Pulmonary Vascular Tone in PPHN: Persistent pulmonary
hypertension of the newborn
(PPHN) occurs as a primary developmental defect or as a condition
secondary to other diseases
such as meconium aspiration syndrome (MAS), pneumonia, sepsis, hyaline
membrane disease,
congenital diaphragmatic hernia (CDH), and pulmonary hypoplasia. In
these states, pulmonary
vascular resistance (PVR) is high, which results in hypoxemia
secondary to right-to-left shunting
of blood through the patent ductus arteriosus and foramen ovale.
Inhalation of nitric oxide reduces
the oxygenation index (OI= mean airway pressure in cm H
2
O x fraction of inspired ox